1. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients
- Author
-
Raphaël Chiron, Laurent Debarbieux, Frédérique Carrié, Nicolas Molinari, Isabelle Sermet, Isabelle Vachier, Jean-Paul Pirnay, Emilie Saussereau, Nicolas Dufour, Benoit Godbert, Daniel De Vos, Debarbieux, Laurent, Cellule Pasteur UPMC, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris] (IP), Biologie Moléculaire du Gène chez les Extrêmophiles (BMGE), Institut Pasteur [Paris] (IP), Département des Maladies Respiratoires [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Service de Pneumologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de recherche Croissance et signalisation (UMR_S 845), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Cellule Pasteur, Université Paris Diderot - Paris 7 (UPD7)-PRES Sorbonne Paris Cité, Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital [Brussels], PHAGESPOIRS, Mathématiques, Informatique et STatistique pour l'Environnement et l'Agronomie (MISTEA), Institut National de la Recherche Agronomique (INRA)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), This work was supported by Vaincre la Mucoviscidose, the French Cystic Fibrosis Foundation [RC20120600714/1/1/141], and Programme Transversal de Recherches [417] from Institut Pasteur and Assistance Publique Hôpitaux de Paris., Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris], Institut Pasteur [Paris], Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de la Recherche Agronomique (INRA), PRES Sorbonne Paris Cité-Université Paris Diderot - Paris 7 (UPD7), Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)-Institut National de la Recherche Agronomique (INRA), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut Pasteur [Paris], Biologie Moléculaire du Gène chez les Extrêmophiles ( BMGE ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Arnaud de Villeneuve, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Centre de recherche Croissance et signalisation ( UMR_S 845 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Diderot - Paris 7 ( UPD7 ) -PRES Sorbonne Paris Cité, Mathématiques, Informatique et STatistique pour l'Environnement et l'Agronomie ( MISTEA ), and Institut National de la Recherche Agronomique ( INRA ) -Institut national d’études supérieures agronomiques de Montpellier ( Montpellier SupAgro )
- Subjects
Male ,Time Factors ,Cystic Fibrosis ,medicine.medical_treatment ,Antibiotics ,pulmonary infection ,[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,medicine.disease_cause ,MESH: Bacterial Load ,Cystic fibrosis ,MESH : Cross-Sectional Studies ,MESH: Sputum ,MESH : Female ,MESH: Microbial Viability ,MESH: Middle Aged ,biology ,MESH: Pseudomonas Infections ,General Medicine ,MESH : Adult ,MESH : Pseudomonas aeruginosa ,Middle Aged ,MESH : Pseudomonas Infections ,3. Good health ,Biological Therapy ,Chronic infection ,medicine.anatomical_structure ,Infectious Diseases ,MESH: Young Adult ,Pseudomonas aeruginosa ,MESH: Pseudomonas aeruginosa ,Female ,MESH : Bacterial Load ,medicine.symptom ,Pseudomonas Phages ,MESH : Time Factors ,Adult ,Microbiology (medical) ,phage therapy ,Phage therapy ,Adolescent ,MESH: Cystic Fibrosis ,medicine.drug_class ,MESH : Male ,MESH : Young Adult ,MESH: Pseudomonas Phages ,Microbiology ,Young Adult ,MESH: Cross-Sectional Studies ,MESH : Adolescent ,MESH : Cystic Fibrosis ,medicine ,Humans ,MESH : Middle Aged ,Pseudomonas Infections ,MESH: Adolescent ,Microbial Viability ,MESH: Humans ,MESH : Humans ,MESH: Time Factors ,MESH : Microbial Viability ,Sputum ,MESH: Adult ,medicine.disease ,biology.organism_classification ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,Bacterial Load ,MESH: Male ,Cross-Sectional Studies ,MESH : Pseudomonas Phages ,MESH : Sputum ,[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,MESH: Biological Therapy ,MESH: Female ,MESH : Biological Therapy ,Bacteria ,Respiratory tract - Abstract
International audience; Bacteriophages have been shown to be effective for treating acute infections of the respiratory tract caused by antibiotic-resistant bacteria in animal models, but no evidence has yet been presented of their activity against pathogens in complex biological samples from chronically infected patients. We assessed the efficacy of a cocktail of ten bacteriophages infecting Pseudomonas aeruginosa following its addition to 58 sputum samples from cystic fibrosis (CF) patients collected at three different hospitals. Ten samples that did not contain P. aeruginosa were not analysed further. In the remaining 48 samples, the addition of bacteriophages led to a significant decrease in the levels of P. aeruginosa strains, as shown by comparison with controls, taking two variables (time and bacteriophages) into account (p = 0.024). In 45.8% of these samples, this decrease was accompanied by an increase in the number of bacteriophages. We also tested each of the ten bacteriophages individually against 20 colonies from each of these 48 samples and detected bacteriophage-susceptible bacteria in 64.6% of the samples. An analysis of the clinical data revealed no correlation between patient age, sex, duration of P. aeruginosa colonization, antibiotic treatment, FEV1 (forced expiratory volume in the first second) and the efficacy of bacteriophages. The demonstration that bacteriophages infect their bacterial hosts in the sputum environment, regardless of the clinical characteristics of the patients, represents a major step towards the development of bacteriophage therapy to treat chronic lung infections.
- Published
- 2014
- Full Text
- View/download PDF